海外の治験の状況「1」での検索結果
98件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Available
- International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
- Philadelphia chromosome-positive acute lymphoblastic leukemia MedDRA version: 20.0 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- France
- 2018-04-17
Not Available
- HLH-2004. Hemophagocytic Lymphohistiocytosis Study Group. Treatment Protocol of the Second International HLH Study 2004. - HLH-2004
- Hemophagocytic Lymphohistiocytosis (HLH), a life-threatening disease usually occurring in early childhood. HLH-2004 is an international treatment protocol which will be compared with the previous HLH-94 protocol. In HLH-2004 the cyclosporine treatment will be introduced at the start of therapy instead of after 8 weeks. Intrathecal therapy will consist of methotrexate in combination with prednisolone instead of methotrexate alone. Only a minority of the patients will receive intrathecal therapy.
- Norway
- 2005-08-26
Not Available
- A PHASE II, SINGLE-CENTRE, INVESTIGATOR-BLIND, PARALLEL GROUP CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 1% CICLOPIROX OLAMINE (BATRAFEN® CREAM), COMPARED TO 1% HYDROCORTISONE ACETATE (HC45® CREAM), COMPARED TO A TOPICAL EMOLLIENT (E45® CREAM), IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE ATOPIC ECZEMA
- Mild to moderate atopic eczema MedDRA version: 8.0 Level: LLT Classification code 10003641
- United Kingdom
- 2005-07-01
Not Available
- A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized Background Therapy in HIV-1 Infected Subjects Who Have Failed and/or Harbor HIV with Resistance Mutations to NRTIs, PIs, and NNRTIs - DECLARE 1
- HIV-1
- United Kingdom
- 2006-02-24
Not Available
- A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours
- Children and adolescents with a primary brain tumour after first line therapy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Germany
- 2014-01-14
Not Available
- Evaluation of preventive efficacy of valaciclovir hydrochloride in herpes simplex virus infection for hematopoietic stem cell transplantation patients.
- Herpes simplex virus (HSV) infection before and after hematopoietic stem cell transplantation.;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Japan
- 2016-12-21
Not Available
- Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.
- Spinal Muscular Atrophy (type 2 or type 3 non ambulant patients aged 3-25 years) MedDRA version: 12.1 Level: LLT Classification code 10041582 Term: Spinal muscular atrophy
- Belgium, France, Germany, Italy, Netherlands, United Kingdom
- 2010-06-01
Not Available
- Raltegravir/Lamivudine Drug Interaction Study
- HIV-1 Infection;Therapeutic area: Body processes [G] - Physiological processes [G07]
- Canada
- 2015-05-22
Not Available
- A two-staged, open label, single dose, two period, two-sequence, crossover study to compare the bioavailability of 2 mg Glycopyrronium Bromide from a new oral solution (2 mg/5 ml) (Test Product) with that of 2 mg Glycopyrronium Bromide from Cuvposa (1 mg/5 ml) Solution (Reference product) in at least 36 healthy male and female subjects under fasting conditions.
- Sialorrhoea (chronic pathological drooling);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- South Africa
- 2014-03-18
Not Available
- TMC114-TiDP29-C228 – A safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (rtv) in HIV 1 infected children from 3 years to below 6 years of age
- The purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced HIV 1 infected children aged from 3 years to MedDRA version: 16.1 Level: LLT Classification code 10020192 Term: HIV-1 System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Brazil, India, Kenya, South Africa
- 2014-02-25
